LOQTORZI

(Toripalimab-tpzi)

Phase 2Small molecule

CCoherus Oncology, Inc.

LOQTORZI is one of 96 small molecule programs targeting Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Squamous Cell CarcinomaRecruiting

Ovarian CancerNot yet recruiting

Squamous Cell CarcinomaPhase 2

Recruiting

Ovarian CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

232 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

33 2

Keytruda

Merck & Co.

Phase 3

28 3

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

35 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 5

Femara

Novartis

Phase 3

8 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

23 7

Rubraca

Bristol-Myers Squibb

Phase 3

6 8

Trodelvy

Gilead

Phase 3

4 9

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Taxotere

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Ovarian Cancer

NCT05479045

Q3 2029

Phase 2Recruiting

Squamous Cell Carcinoma

NCT07214987

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Not yet recruiting·GGeorgetown University·Phase 2·NCT05479045·24 enrolled

Squamous Cell Carcinoma1 trial

A Phase 2 Study of Toripalimab in Combination With Cisplatin and Docetaxel (PDT) for Induction Therapy in CPS-Positive Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting·MMassachusetts General Hospital·Phase 2·NCT07214987·26 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 27, 2023

LOQTORZI

BLA BLA761240

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Toripalimab-tpzi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Toripalimab-tpzi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Toripalimab-tpzi. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761240). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Coherus Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCoherus Oncology, Inc.

LOQTORZI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q3 2029

Trials by Indication[1]

Ovarian Cancer1 trial

Squamous Cell Carcinoma1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News